2097.HK

Leading bubble tea chain Mixue Group (2097.HK) on Wednesday said its revenue reached 24.83 billion yuan ($3.42 billion) last year, up 22.3% from 2023, according to its first financial report since its IPO earlier this month. Its annual net profit jumped 41.4% to 4.44 billion yuan during the period.

The company attributed the improved profit to a more efficient supply chain and lower costs for some raw materials, which boosted its gross margin for merchandise and equipment sales from 28.8% in 2023 to 31.6% last year.

The company operated 46,479 stores globally at the end of last year, up by 8,914 from the start of the year. That included 41,584 stores in China and 4,895 overseas. The company plans to continue expanding its domestic network while focusing on Southeast Asia for its global business, with potential entry into other regions when conditions permit.

Mixue’s shares opened up 1.1% at HK$415 on Thursday. The stock has more than doubled since its trading debut earlier this month.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…